Skip to main navigation

Search for:

Search

Rubius Therapeutics

About Us
Our Science
Our Pipeline
Investors & Media
Careers
Contact

Menu Search

Press Releases

Year

September 1, 2021

Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021

August 30, 2021

Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer

August 9, 2021

Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

July 29, 2021

Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer

July 22, 2021

Rubius Therapeutics to Announce Second Quarter 2021 Financial Results

July 15, 2021

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

June 23, 2021

Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors

May 20, 2021

Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference

May 19, 2021

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

May 12, 2021

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 25

Print Page

RSS Feeds

Share Page

Email Alerts

Contact Us

399 Binney St, Suite 300
Cambridge, MA 02139 617-679-9600

Share

LinkedIn Twitter

Home
About Us
Our Science
Our Pipeline
Investors
Careers
Sitemap
Terms of Use
Privacy Policy

© Rubius Therapeutics, Inc. 2021. All Rights Reserved. RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners.

Facebook
Twitter
LinkedIn